Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development

被引:0
|
作者
Yanying Huo
Pier Selenica
Amar H. Mahdi
Fresia Pareja
Kelly Kyker-Snowman
Ying Chen
Rahul Kumar
Arnaud Da Cruz Paula
Thais Basili
David N. Brown
Xin Pei
Nadeem Riaz
Yongmei Tan
Yu-Xiu Huang
Tao Li
Nicola J. Barnard
Jorge S. Reis-Filho
Britta Weigelt
Bing Xia
机构
[1] Rutgers Cancer Institute of New Jersey,Department of Radiation Oncology
[2] Rutgers Robert Wood Johnson Medical School,Department of Pathology
[3] Memorial Sloan Kettering Cancer Center,Department of Radiation Oncology
[4] Memorial Sloan Kettering Cancer Center,Department of Pathology and Laboratory Medicine
[5] Stomatological Hospital of Guangzhou Medical University,Department of Physiology, College of Medicine
[6] The First Affiliated Hospital of Fujian Medical University,Centre for Brain Research
[7] Rutgers Robert Wood Johnson Medical School,undefined
[8] Al-Mustansiriyah University,undefined
[9] Indian Institute of Science (IISc),undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Inherited mutations in BRCA1, BRCA2, and PALB2 cause a high risk of breast cancer. Here, we conducted parallel conditional knockout (CKO) of Brca1, Palb2, and Brca2, individually and in combination, along with one copy of Trp53, in the mammary gland of nulliparous female mice. We observed a functional equivalence of the three genes in their basic tumor-suppressive activity, a linear epistasis of Palb2 and Brca2, but complementary roles of Brca1 and Palb2 in mammary tumor suppression, as combined ablation of either Palb2 or Brca2 with Brca1 led to delayed tumor formation. Whole-exome sequencing (WES) revealed both similarities and differences between Brca1 and Palb2 or Brca2 null tumors. Analyses of mouse mammary glands and cultured human cells showed that combined loss of BRCA1 and PALB2 led to high levels of reactive oxygen species (ROS) and increased apoptosis, implicating oxidative stress in the delayed tumor development in Brca1;Palb2 double CKO mice. The functional complementarity between BRCA1 and PALB2/BRCA2 and the role of ROS in tumorigenesis require further investigation.
引用
收藏
相关论文
共 50 条
  • [21] Identification and management of pathogenic mutations in BRCA1, BRCA2, and PALB2 in a tumor-only genomic testing program.
    Bychkovsky, Brittany L.
    Li, Tianyu
    Sotelo, Jilliane
    Tayob, Nabihah
    Mercado, Joanna
    Gomy, Israel
    Chittenden, Anu B.
    Kane, Sarah R.
    Stokes, Samantha
    Hughes, Melissa E.
    Kim, Ji Seok
    Awad, Mark M.
    Konstantinopoulos, Panagiotis A.
    Wolpin, Brian M.
    Taplin, Mary-Ellen
    Johnson, Bruce E.
    Lindeman, Neal Ian
    MacConaill, Laura E.
    Garber, Judy Ellen
    Lin, Nancy U.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] BRCA1 and BRCA2 in mammary gland development and tumorigenesis - Introduction
    Bradley, A
    Medina, D
    JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 1998, 3 (04) : 363 - 364
  • [23] Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families
    Pylkas, Katri
    Erkko, Hannele
    Nikkila, Jenni
    Solyom, Szilvia
    Winqvist, Robert
    BMC CANCER, 2008, 8 (1)
  • [24] Are Trp53 rescue of Brca1 embryonic lethality and Trp53/Brca1breast cancer association related?
    Kimberly A McAllister
    Roger W Wiseman
    Breast Cancer Research, 4
  • [25] Structural basis for recruitment of BRCA2 by PALB2
    Oliver, Antony W.
    Swift, Sally
    Lord, Christopher J.
    Ashworth, Alan
    Pearl, Laurence H.
    EMBO REPORTS, 2009, 10 (09) : 990 - 996
  • [26] Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
    Max M. Wattenberg
    Daniella Asch
    Shun Yu
    Peter J. O’Dwyer
    Susan M. Domchek
    Katherine L. Nathanson
    Mark A. Rosen
    Gregory L. Beatty
    Evan S. Siegelman
    Kim A. Reiss
    British Journal of Cancer, 2020, 122 : 333 - 339
  • [27] NGS-based BRCA1, BRCA2, and PALB2 mutation testing in Iranian population with breast cancer
    Ebrahimi, E.
    Zendehdel, K.
    Sellars, E.
    Ghiasvand, R.
    Harirchi, I.
    Shirkoohi, R.
    Akbari, M. R.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 531 - 532
  • [28] Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families
    Katri Pylkäs
    Hannele Erkko
    Jenni Nikkilä
    Szilvia Sólyom
    Robert Winqvist
    BMC Cancer, 8
  • [29] Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
    Wattenberg, Max M.
    Asch, Daniella
    Yu, Shun
    O'Dwyer, Peter J.
    Domchek, Susan M.
    Nathanson, Katherine L.
    Rosen, Mark A.
    Beatty, Gregory L.
    Siegelman, Evan S.
    Reiss, Kim A.
    BRITISH JOURNAL OF CANCER, 2020, 122 (03) : 333 - 339
  • [30] Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland
    Wojcik, P.
    Jasiowka, M.
    Strycharz, E.
    Sobol, M.
    Hodorowicz-Zaniewska, D.
    Skotnicki, P.
    Byrski, T.
    Blecharz, P.
    Marczyk, E.
    Cedrych, I.
    Jakubowicz, J.
    Lubinski, J.
    Sopik, V.
    Narod, S.
    Pierzchalski, P.
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2016, 14